2

Sitaxsentan sodium

2 Cited Publications

Cat. No.: HY-11103

CAS No.: 210421-74-2

Purity: 98.83%

Synonyms: IPI 1040 sodium; TBC11251 sodium

Target:

Endothelin Receptor TGF-β Receptor

Research Areas:

Cardiovascular Disease Metabolic Disease

Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Sitaxsentan

2 Cited Publications

Cat. No.: HY-76520

CAS No.: 184036-34-8

Synonyms: IPI 1040; TBC-11251

Target:

Endothelin Receptor TGF-β Receptor

Research Areas:

Cardiovascular Disease Metabolic Disease

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Tasisulam

1 Cited Publications

Cat. No.: HY-14804

CAS No.: 519055-62-0

Purity: 99.77%

Synonyms: LY 573636

Target:

Molecular Glues Apoptosis

Research Areas:

Cancer

Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

RAPTA-C

Cat. No.: HY-130326

CAS No.: 372948-28-2

Purity: 99.30%

Synonyms: Ru(η6-p-cymene)Cl2(pta)

Target:

Apoptosis

Research Areas:

Inflammation/Immunology Cancer

RAPTA-C is a ruthenium-based antimetastatic agent. RAPTA-C binds chromatin histones and interacts with DNA, leading to pH-dependent DNA damage and hypoxia selectivity. RAPTA-C inhibits angiogenesis, microvessel density, tumor growth, invasion, and proliferation, and induces apoptosis through the mitochondrial pathway, G2/M phase arrest, quiescence, and vascular normalization. RAPTA-C can be used in research on ovarian cancer, colorectal adenocarcinoma, breast cancer metastasis, and Ehrlich ascites carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Tasisulam sodium

Cat. No.: HY-14804A

CAS No.: 519055-63-1

Synonyms: LY 573636 sodium

Target:

Apoptosis

Research Areas:

Cancer

Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Tolafentrine

Cat. No.: HY-W700639

CAS No.: 139308-65-9

Target:

Phosphodiesterase (PDE)

Research Areas:

Neurological Disease

Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Sitaxsentan sodium (Standard)

Cat. No.: HY-11103R

CAS No.: 210421-74-2

Synonyms: IPI 1040 sodium (Standard); TBC11251 sodium (Standard)

Target:

Endothelin Receptor Reference Standards TGF-β Receptor

Research Areas:

Cardiovascular Disease Metabolic Disease

Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Sitaxsentan-13C6

Cat. No.: HY-76520S

Synonyms: IPI 1040-¹³C₆ ; TBC-11251-¹³C₆

Sitaxsentan- ¹³C₆ (IPI 1040- ¹³C₆) is ¹³C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Anti-CD160 Antibody (MAT 302)

Cat. No.: HY-P992201

Synonyms: CL1-R2

Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .

Compare

loading...